Forza Innovations Inc Stock: price and insider trades · United States
Forza Innovations Inc: what insiders have been doing
Every trade that managers of Forza Innovations Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. No insider at Forza Innovations Inc has published a filing in the past twelve months. The most recent one dates from 5 November 2021.
The full history, which starts in 2021, counts no purchases against 7 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended June 2023 · cache
- 2,000 shares@ US$0.300.0% of flowCommon StockSEC:0001844844-21-000007:1
- 5,000 shares@ US$0.255.7% of flowCommon StockSEC:0001844844-21-000007:0
- 5,000 shares@ US$0.173.9% of flowCommon StockSEC:0001844844-21-000006:0
- 3,300 shares@ US$0.25130.0% of flowCommon StockSEC:0001844844-21-000002:1
- 27,693 shares@ US$0.1836Common StockSEC:0001844844-21-000002:2
- 400,000 shares@ US$0.0590.4% of flowCommon StockSEC:0001844844-21-000002:0
- 17,000,000 sharesCommon SharesSEC:0001607062-21-000012:0
- 10,000,000 sharesSeries B PreferredSEC:0001607062-21-000012:1
8 of 8 declarations
About Forza Innovations Inc
Forza Innovations Inc. is a U.S.-based micro-cap issuer with a history of SEC reporting and insider transaction disclosures, but investors should be careful not to confuse its current profile with a large, highly liquid NYSE/NASDAQ-listed consumer or medical technology name. The company is tied to the United States, with a business address previously disclosed in San Diego, California, while its SEC filings also reflect a restructuring history that included Canadian links during the control change process. In market terms, it remains a small, speculative name, so the investment case is primarily driven by corporate execution rather than scale, brand power, or broad institutional coverage.
Operationally, Forza Innovations has undergone a meaningful strategic pivot. The company was originally involved in precision CNC manufacturing and metal fabrication, but its filings indicate that it moved into a health-tech wearable performance business by 2021. Today, its product narrative centers on the WarmUp line, including J4 Sport, J4 X, and J4 Fitbelt. These are wearable back-compression devices designed to help users relax, warm up, loosen, or ease stiff and sore muscles. The company describes the therapeutic concept as heat-related soft-tissue temperature changes that may reduce joint stiffness and inflammation. For an equity analyst, this means Forza is positioned less as a diversified industrial operator and more as a niche wearable-health commercialization story.
Read moreShow less
Founded in 2014, Forza’s corporate history includes a change of control in 2021 and a subsequent effort to rebuild the business around health-tech innovation. Management has also framed acquisitions as part of the growth plan. A notable example is the acquisition of Sustainable Origins, a used-cooking-oil recycling business aimed at biodiesel-related revenue streams. That transaction suggests a dual-track strategy: supporting product development while using operating assets to help fund the core WarmUp business. This is important because the company appears to be in a transition phase where cash generation, product validation, and balance-sheet flexibility likely matter more than current scale.
From a competitive standpoint, Forza operates in a fragmented market for wearable wellness, therapeutic support, and recovery accessories. Its competitive positioning depends on product differentiation, intellectual property, manufacturing execution, and distribution reach. The company’s strengths are its focused product concept and the optionality embedded in adjacent operating assets. Its risks are typical of an early-stage micro-cap: limited disclosure granularity, commercialization risk, financing dependence, and uncertain demand traction. Geographically, its commercial focus appears primarily U.S.-oriented, with no evidence of a broad international footprint at this stage. Recent developments worth monitoring include SEC filing activity, insider transactions reported on Form 4, and whether the company can translate its repositioning into sustainable operating momentum.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
